Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease

Biancheri, Paolo, Di Sabatino, Antonio, Rovedatti, Laura, Giuffrida, Paolo, Calarota, Sandra A, Vetrano, Stefania, Vidali, Francesca, Pasini, Alessandra, Danese, Silvio, Corazza, Gino R and MacDonald, Thomas T (2013) Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. Inflammatory Bowel Diseases, 19 (2). pp. 259-264. ISSN 1078-0998

Full text not available from this repository.

Abstract

BACKGROUND: Mucosal addressin cell-adhesion molecule (MAdCAM)-1, which is overexpressed on gut endothelium in active Crohn's disease (CD), promotes intestinal recruitment of integrin α(4)β(7)(*) T cells that sustain chronic inflammation. As tumor necrosis factor alpha (TNF)-α, a cytokine centrally involved in CD, modulates gut endothelial adhesion molecules, we here explored the in vivo and ex vivo effects of TNF-α blockade on MAdCAM-1 expression in CD. METHODS: MAdCAM-1 was determined by immunoblotting in colonic biopsies collected before and 10 weeks after either infliximab or adalimumab treatment in CD patients, and in CD biopsies incubated with either infliximab or adalimumab or control IgG(1). Integrin β(7)(*) circulating T cells were analyzed by flow cytometry. RESULTS: MAdCAM-1 significantly decreased after either infliximab or adalimumab treatment in responder but not in nonresponder patients. In parallel, an increase of circulating β(7)(*) T cells was found in responder patients only. A marked downregulation of MAdCAM-1 was observed in CD biopsies cultured with either infliximab or adalimumab in comparison to IgG(1)-treated biopsies. CONCLUSIONS: Our findings showing that MAdCAM-1 is downregulated by TNF-α blockade point to a novel mechanism of action of anti-TNF-α antibodies in CD.

Item Type:	Article
Uncontrolled Keywords:	adalimumab,adult,aged,pharmacology,pharmacology,pharmacology,metabolism,blotting, western,drug effects,drug therapy,drug effects,drug administration schedule,female,flow cytometry,humans,metabolism,infliximab,metabolism,male,middle aged,metabolism,metabolism,treatment outcome
Depositing User:	LivePure Connector
Date Deposited:	07 Aug 2018 16:30
Last Modified:	21 Oct 2022 19:35
URI:	https://ueaeprints.uea.ac.uk/id/eprint/67983
DOI:	10.1097/MIB.0b013e31828100a4

Actions (login required)

View Item